RxDoctor Payments Data

John Lancaster, MD

Family Medicine · Center Point, IANPI 1487622098

Payments from drug & device makers

$6,378in general payments, 2019–2025

Across 437 payments — averaging $14.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • AbbVie$790
  • AstraZeneca$777
  • Novo Nordisk$525
  • Lilly USA, LLC$486
  • Boehringer Ingelheim$440
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$6,372100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,378 in reported general payments places this provider in the 95th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$231,659
Medicare patients
264
Services billed
5,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$141,171
JardianceEmpagliflozin83$95,414
EliquisApixaban96$74,650
FarxigaDapagliflozin Propanediol24$30,053
XareltoRivaroxaban33$26,803
VraylarCariprazine Hcl12$16,050
RybelsusSemaglutide15$14,671
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,779
Lantus SolostarInsulin Glargine,hum.Rec.Anlog55$11,896
MyrbetriqMirabegron11$11,098
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$9,630
Dexlansoprazole DrDexlansoprazole23$8,373
Breo ElliptaFluticasone/Vilanterol14$6,234
BelsomraSuvorexant12$5,111
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen187$3,798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$525$155,842119 claims
Boehringer IngelheimJardiance$440$95,41483 claims
PfizerEliquis$1,245$74,65096 claims
AstraZenecaFarxiga$777$30,05324 claims
Johnson & JohnsonXarelto$195$26,80333 claims
GSKTrelegy Ellipta, Breo Ellipta$192$20,01333 claims
AbbVieVraylar$790$16,05012 claims
Astellas Pharma US IncMyrbetriq$40$11,09811 claims
MerckBelsomra$155$5,11112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Center Point

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →